Submit to Special Issue Submit Abstract to Special Issue Review for IJMS Propose a Special Issue

Journal Menu

Journal Browser

Molecular Mechanisms of Tumor Progression and New Therapeutic Strategies for Urological Cancers 2.0

Print Special Issue Flyer
Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: 15 August 2024 | Viewed by 4277

Share This Special Issue

Special Issue Editors

Dr. Vicenç Ruiz de Porras

E-Mail Website
Guest Editor

1. Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B·ARGO), Ctra. Can Ruti-Camí de les Escoles s/n, 08916 Badalona, Spain
2. Germans Trias i Pujol Research Institute (IGTP), Ctra. Can Ruti-Camí de les escoles s/n, 08916 Badalona, Spain
Interests: metastatic prostate cancer; bladder cancer; therapy resistance; chemotherapy; predictive biomarkers
Special Issues, Collections and Topics in MDPI journals

Dr. Albert Font

E-Mail Website
Guest Editor

Badalona–Badalona Applied Research Group in Oncology (B·ARGO), Catalan Institute of Oncology, 08916 Badalona, Spain
Interests: genitourinary tumors
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Urological tumors comprise bladder, prostate, renal, upper urinary tract, and germ-cell tumors, among others. The incidence of urological tumors has increased significantly over the past 40 years. In fact, all of them rank in the top ten list of human cancers and account for up to 33% of malignancies affecting the male population. Their different pathogenetic mechanisms and their varied diagnostic and therapeutic approaches represent a challenge in clinical practice. Thus, treatment for urologic cancers depends on several factors, such as the tumor’s grade and stage. Common options include surgery, chemotherapy, and radiation therapy.

However, although the therapeutic landscape of urological tumors has significantly improved in recent years with the incorporation of new treatment options such as immunotherapy and target therapies, understanding the molecular mechanisms of tumor progression and therapy resistance will help us to develop novel treatment strategies and predict drug response toward precision medicine.

This Special Issue of the International Journal of Molecular Sciences therefore encompasses original and review articles on the molecular mechanisms leading to tumor progression and resistance to current treatment options, new therapeutic strategies, as well as new prognostic and predictive biomarkers for urological tumors.

More published papers could be found in the closed Special Issue: Molecular Mechanisms of Tumor Progression and New Therapeutic Strategies for Urological Cancers.

Dr. Vicenç Ruiz de Porras
Dr. Albert Font Pous
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

prostate cancer
bladder cancer
renal cell carcinoma
upper urinary tract tumors
testicular cancer
predictive and prognostic biomarkers
tumor progression
novel treatment strategies
chemotherapy
immunotherapy
target therapies
drug resistance mechanisms
tumor microenvironment
precision medicine

Published Papers (4 papers)

Download All Papers

Research

Jump to: Other

13 pages, 2432 KiB

Open AccessArticle

Interleukin-1β/Interleukin (IL)-1-Receptor-Antagonist (IL1-RA) Axis in Invasive Bladder Cancer—An Exploratory Analysis of Clinical and Tumor Biological Significance

by Marko Vukovic, Jorge M. Chamlati, Jörg Hennenlotter, Tilman Todenhöfer, Thomas Lütfrenk, Sebastian Jersinovic, Igor Tsaur, Arnulf Stenzl and Steffen Rausch

Int. J. Mol. Sci. 2024, 25(4), 2447; https://doi.org/10.3390/ijms25042447 - 19 Feb 2024

Viewed by 909

Abstract

Previous data indicate a role of IL-1 and IL-1RA imbalance in bladder carcinoma (BC); the inhibition of IL-1 signaling might be considered a treatment option. Objective: To assess expression patterns and the prognostic role of IL-1β and IL-1RA in invasive BC and to evaluate their interaction with AKT signaling and proliferation. The study included two independent cohorts of n = 92 and n = 102 patients who underwent a radical cystectomy for BC. Specimen from BC and benign urothelium (n = 22 and n = 39) were processed to a tissue microarray and immunohistochemically stained for IL-1β, IL-1RA, AKT, and Ki-67. Expression scores were correlated to clinical variables and Ki-67 and AKT expression. An association with outcome was assessed using Wilcoxon Kruskal–Wallis tests, Chi-square tests or linear regression, dependent on the variable’s category. Kaplan–Meier and Cox proportional hazard analyses were used to estimate recurrence-free (RFS), cancer-specific (CSS) and overall survival (OS). Both IL-1β and IL-1RA were significantly overexpressed in invasive BC compared to benign urothelium in both cohorts (p < 0.005). IL-1β was associated with vascular invasion (210 vs. 183, p < 0.02), lymphatic invasion (210 vs. 180, <0.05) and G3 cancer (192 vs. 188, <0.04). The survival analysis revealed favorable RFS, CSS, and OS in the case of high IL-1β expression (p < 0.02, <0.03, and <0.006, respectively). Multivariate analyses revealed an independent impact of (low) IL1β expression on RFS, CSS, and OS. The IL-1β and IL-1β/IL-1RA ratios were positively correlated to the AKT expression (p < 0.05 and <0.01, respectively). Additionally, the high expression of Ki-67 (>15%) correlated with higher levels of IL-1β (p = 0.01). The overexpression of IL-1β and IL-1RA is frequently found in BC, with a prognostic significance observed for the IL-1β protein expression. The observed link between the IL-1β/IL-1RA axis and AKT signaling may indicate possible autophagy activation processes besides the known tumor-promoting effects of AKT. Full article

(This article belongs to the Special Issue Molecular Mechanisms of Tumor Progression and New Therapeutic Strategies for Urological Cancers 2.0)

► Show Figures

Figure 1

10 pages, 915 KiB

Open AccessCommunication

Tumor-Agnostic Circulating Tumor DNA Testing for Monitoring Muscle-Invasive Bladder Cancer

by Raquel Carrasco, Mercedes Ingelmo-Torres, Ramón Trullas, Fiorella L. Roldán, Leonardo Rodríguez-Carunchio, Lourdes Juez, Joan Sureda, Antonio Alcaraz, Lourdes Mengual and Laura Izquierdo

Int. J. Mol. Sci. 2023, 24(23), 16578; https://doi.org/10.3390/ijms242316578 - 21 Nov 2023

Cited by 1 | Viewed by 879

Abstract

Circulating tumor DNA (ctDNA) has recently emerged as a real-time prognostic and predictive biomarker for monitoring cancer patients. Here, we aimed to ascertain whether tumor-agnostic ctDNA testing would be a feasible strategy to monitor disease progression and therapeutic response in muscle-invasive bladder cancer (MIBC) patients after radical cystectomy (RC). Forty-two MIBC patients who underwent RC were prospectively included. Blood samples from these patients were collected at different follow-up time points. Two specific mutations (TERT c.1-124C>T and ATM c.1236-2A>T) were analyzed in the patients’ plasma samples by droplet digital PCR to determine their ctDNA status. During a median follow-up of 21 months, 24% of patients progressed in a median of six months. ctDNA status was identified as a prognostic biomarker of tumor progression before RC and 4 and 12 months later (HR 6.774, HR 3.673, and HR 30.865, respectively; p < 0.05). Lastly, dynamic changes in ctDNA status between baseline and four months later were significantly associated with patient outcomes (p = 0.045). In conclusion, longitudinal ctDNA analysis using a tumor-agnostic approach is a potential tool for monitoring MIBC patients after RC. The implementation of this testing in a clinical setting could improve disease management and patients’ outcomes. Full article

(This article belongs to the Special Issue Molecular Mechanisms of Tumor Progression and New Therapeutic Strategies for Urological Cancers 2.0)

► Show Figures

Figure 1

12 pages, 2879 KiB

Open AccessArticle

GABBR2 as a Downstream Effector of the Androgen Receptor Induces Cisplatin Resistance in Bladder Cancer

by Mohammad Amin Elahi Najafi, Masato Yasui, Yuki Teramoto, Tomoyuki Tatenuma, Guiyang Jiang and Hiroshi Miyamoto

Int. J. Mol. Sci. 2023, 24(18), 13733; https://doi.org/10.3390/ijms241813733 - 6 Sep 2023

Viewed by 1024

Abstract

The precise molecular mechanisms responsible for resistance to cisplatin-based chemotherapy in patients with bladder cancer remain elusive, while we have indicated that androgen receptor (AR) activity in urothelial cancer is associated with its sensitivity. Our DNA microarray analysis in control vs. AR-knockdown bladder cancer sublines suggested that the expression of a GABA B receptor GABBR2 and AR was correlated. The present study aimed to determine the functional role of GABBR2 in modulating cisplatin sensitivity in bladder cancer. AR knockdown and dihydrotestosterone treatment considerably reduced and induced, respectively, GABBR2 expression, and the effect of dihydrotestosterone was at least partially restored by an antiandrogen hydroxyflutamide. A chromatin immunoprecipitation assay further revealed the binding of AR to the promoter region of GABBR2 in bladder cancer cells. Meanwhile, GABBR2 expression was significantly elevated in a cisplatin-resistant bladder cancer subline, compared with control cells. In AR-positive bladder cancer cells, knockdown of GABBR2 or treatment with a selective GABA B receptor antagonist, CGP46381, considerably enhanced the cytotoxic activity of cisplatin. However, no additional effect of CGP46381 on cisplatin-induced growth suppression was seen in GABBR2-knockdown cells. Moreover, in the absence of cisplatin, CGP46381 treatment and GABBR2 knockdown showed no significant changes in cell proliferation or migration. These findings suggest that GABBR2 represents a key downstream effector of AR signaling in inducing resistance to cisplatin treatment. Accordingly, inhibition of GABBR2 has the potential of being a means of chemosensitization, especially in patients with AR/GABBR2-positive bladder cancer. Full article

(This article belongs to the Special Issue Molecular Mechanisms of Tumor Progression and New Therapeutic Strategies for Urological Cancers 2.0)

► Show Figures

Figure 1

Other

Jump to: Research

8 pages, 1848 KiB

Open AccessCase Report

Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin

by Catherine C. Fahey, Caroline A. Nebhan, Sally York, Nancy B. Davis, Paula J. Hurley, Jennifer B. Gordetsky and Kerry R. Schaffer

Int. J. Mol. Sci. 2023, 24(22), 16109; https://doi.org/10.3390/ijms242216109 - 9 Nov 2023

Cited by 2 | Viewed by 1161

Abstract

Penile squamous cell carcinoma is a rare disease with very limited data to guide treatment decisions. In particular, there is minimal evidence for effective therapies in the metastatic setting. Here, we present a case of metastatic penile squamous cell carcinoma with response to the Nectin-4 inhibitor enfortumab-vedotin-ejfv (EV). EV was selected due to the evidence of the high expression of Nectin-4 in squamous cell carcinomas, including penile carcinoma. The patient had both radiographic and symptomatic improvement after two cycles of treatment, despite having been treated with multiple prior lines of traditional chemotherapy. This case provides support for the use of antibody–drug conjugates (ADC), including EV, in this disease with few other options in the advanced setting. Further studies examining Nectin-4 and ADCs in penile squamous cell carcinoma should be completed, as high-quality evidence is needed to guide treatment after initial progression for these patients. Full article

(This article belongs to the Special Issue Molecular Mechanisms of Tumor Progression and New Therapeutic Strategies for Urological Cancers 2.0)

► Show Figures